Article
Pharmacology & Pharmacy
Wenyi Liang, Kun Zhou, Ping Jian, Zihao Chang, Qiunan Zhang, Yuqi Liu, Shuiming Xiao, Lanzhen Zhang
Summary: Ginsenoside extract has shown beneficial effects on high-fat diet-induced nonalcoholic fatty liver disease by modulating gut microbiota, improving gut barrier function, and regulating metabolic inflammation. It also suppressed NF-kappa B/I kappa B signaling activation and promoted hepatic lipolytic genes while inhibiting lipogenic genes. This suggests that ginsenoside extract may be a potential agent for preventing NAFLD through its prebiotic, anti-inflammatory, and energy-regulatory effects.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Xinyu Wang, Ruosu Zhang, Sailimai Man, Jun Lv, Canqing Yu, Jianchun Yin, Xiaona Wang, Yuhan Deng, Bo Wang, Liming Li, Yuanjie Pang
Summary: This study found that metabolic-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD) are both associated with subclinical atherosclerosis. However, individuals who meet the criteria for one but not the other have limited evidence on the risk of atherosclerosis. The study also found that individuals who meet both definitions or only the definition for MAFLD have a higher risk of subclinical atherosclerosis compared to those with NAFLD alone.
LIVER INTERNATIONAL
(2023)
Article
Cardiac & Cardiovascular Systems
Shuangyang Mo, Yingwei Wang, Xin Yuan, Wenhong Wu, Huaying Zhao, Haixiao Wei, Haiyan Qin, Haixing Jiang, Shanyu Qin
Summary: This study identifies common signature genes, pathways, and immune cells associated with nonalcoholic fatty liver disease (NAFLD) and atherosclerosis (AS) through bioinformatic analysis. The results reveal PLCXD3, CCL19, and PKD2 as common signature genes, and the NLRs signaling pathway and activated CD4 T cells as significant features in both diseases. These findings provide new insights into the molecular mechanisms of NAFLD complicated with AS.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Medicine, Research & Experimental
Congxiang Shao, Lishu Xu, Pingguang Lei, Wei Wang, Shiting Feng, Junzhao Ye, Bihui Zhong
Summary: Metabolomics was used to identify potential metabolite profiles in nonobese metabolic dysfunction-associated fatty liver disease (MAFLD). Diagnostic models combining different metabolites according to BMI categories could improve the accuracy of identifying subclinical carotid atherosclerosis (CAS).
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Won-Yung Lee, Choong-Yeol Lee, Jin-Seok Lee, Chang-Eop Kim
Summary: In this study, a network-based framework was applied to comprehensively identify candidate flavonoids for the prevention and treatment of NAFLD. The effectiveness of the discovered candidates, particularly glycitin, was validated through experiments. The reconstructed flavonoid-target network successfully rediscovered compounds and their potential mechanisms for treating NAFLD. Additionally, glycitin was found to significantly reduce lipid accumulation and inhibit oxidative stress.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Liya Chen, Yao Wang, Weikun Zheng, Hu Zhang, Yan Sun, Yiping Chen, Qi Liu
Summary: This study demonstrates that intermittent hypoxia (IH) has a protective effect on the liver of high-fat and high-fructose diet (HFHFD) fed mice, attenuating lipid accumulation, lipid peroxidation, neutrophil infiltration, and apoptotic process. Additionally, IH alters bile acids composition and shifts hepatic bile acids towards FXR agonism, which contributes to the protection against HFHFD.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Siarhei A. Dabravolski, Evgeny E. Bezsonov, Mirza S. Baig, Tatyana V. Popkova, Alexander N. Orekhov
Summary: The prevalence of NAFLD is rapidly increasing globally, with cardiovascular diseases being the most common cause of mortality in NAFLD patients. Atherogenic dyslipidemia, altered fatty-acid beta-oxidation in liver mitochondria, and various NAFLD-associated genes with cardioprotective effects are key factors connecting NAFLD-mediated dyslipidemia and increased cardiovascular disease risk.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Yuping Zhou, Ze Dai, Kaili Deng, Yubin Wang, Jiamin Ying, Donghui Chu, Jinyue Zhou, Chunlan Tang
Summary: This study used a strategy integrating lipidomics, network pharmacology, and pharmacokinetics to reveal the active components and mechanisms of Eight Zhes Decoction (EZD) against nonalcoholic fatty liver disease (NAFLD). The results showed that EZD attenuated collagen deposition and steatosis in the livers of NAFLD model mice. Naringenin, artemetin, canadine, and bicuculline were identified as the active ingredients of EZD against NAFLD.
JOURNAL OF PHARMACEUTICAL ANALYSIS
(2023)
Article
Biochemistry & Molecular Biology
Francisco Andujar-Vera, Maria Ferrer-Millan, Cristina Garcia-Fontana, Beatriz Garcia-Fontana, Sheila Gonzalez-Salvatierra, Raquel de la Torre, Luis Martinez-Heredia, Blanca Riquelme-Gallego, Manuel Munoz-Torres
Summary: Non-alcoholic fatty liver disease (NAFLD) and atherosclerosis (ATH) may share some molecular connections, but the underlying pathways have not been explored. This study aimed to identify common factors and potential therapeutic targets for both diseases. Differentially expressed genes (DEGs) were analyzed and common DEGs were identified. Protein-protein interaction (PPI) network analysis revealed functional modules and hub genes. Gene Ontology (GO) and pathway analysis were performed. The study found 21 genes with similar regulation in NAFLD and ATH. The hub genes ADAMTS1 and CEBPA were found to be down- and up-regulated, respectively. Functional modules related to protein modification and immune response were identified, with ADAMTS1, ADAMTS4, and CSF3 playing potential key roles.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Min-Kyu Kang, Jung-Gil Park
Summary: The study found that about 11% of NAFLD patients have low skeletal muscle mass. Multivariate analyses showed that LSMM is significantly associated with increased cIMT and the presence of carotid plaques. The proportion of obese NAFLD patients with LSMM having increased cIMT and carotid plaques was significantly higher compared to those without LSMM.
Article
Nutrition & Dietetics
Haitao Jiang, Hua Zhu, Guangming Huo, Shengjie Li, Yulong Wu, Feng Zhou, Chun Hua, Qiuhui Hu
Summary: The study found that Oudemansiella raphanipies-derived polysaccharide (ORPS) has therapeutic effects on high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) in mice. ORPS-1, mainly composed of galactose, fucose, glucose, mannose, and xylose, improves liver function, alleviates liver steatosis, and reduces lipid droplet accumulation. Metabolomics analysis reveals significant alterations in liver metabolic pathways after ORPS-1 treatment.
Article
Biochemistry & Molecular Biology
Pavla Stankova, Otto Kucera, Eva Peterova, Moustafa Elkalaf, David Rychtrmoc, Jan Melek, Miroslav Podhola, Veronika Zubanova, Zuzana Cervinkova
Summary: The study found that after consuming a Western-style diet for 30 weeks, mice showed reduced succinate-activated respiration, decreased SDH activity, reduced expression of the SDH activator sirtuin 3 and SDH subunits, and increased succinate levels. The gene and protein expression of SUCNR1 also decreased in the livers of mice fed the diet, but no signs of oxidative damage were observed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Sisi Lei, Shuai Zhao, Xiaoyan Huang, Yuchao Feng, Zhishang Li, Li Chen, Peiying Huang, Hansu Guan, Haobo Zhang, Qihua Wu, Bojun Chen
Summary: This study investigated the therapeutic effect of Chaihu Shugan powder (CSP) on nonalcoholic fatty liver disease (NAFLD). The results showed that CSP decreased liver inflammation and inhibited hepatic fatty acid synthesis through the inhibition of the TNF alpha/TNFR1 signaling pathway. This study combined network pharmacology with in vivo validation to elucidate the pharmacological mechanisms of CSP.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Gastroenterology & Hepatology
Jonathan Zhi Kai Toh, Xin-Hui Pan, Phoebe Wen Lin Tay, Cheng Han Ng, Jie Ning Yong, Jieling Xiao, Jin Hean Koh, En Ying Tan, Eunice Xiang Xuan Tan, Yock Young Dan, Poay Huan Loh, Roger Foo, Nicholas W. S. Chew, Arun J. Sanyal, Mark D. Muthiah, Mohammad Shadab Siddiqui
Summary: This study aims to explore the association between coronary heart disease (CHD) and nonalcoholic fatty liver disease (NAFLD) by investigating the global prevalence, independent risk factors, and influence of steatosis grade on manifestation of CHD among patients with NAFLD.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Endocrinology & Metabolism
Bin Wang, Zhiyun Zhao, Shanshan Liu, Shuangyuan Wang, Yuhong Chen, Yu Xu, Min Xu, Weiqing Wang, Guang Ning, Mian Li, Tiange Wang, Yufang Bi
Summary: This study investigated the impact of diabetes on subclinical atherosclerosis and cardiovascular disease in individuals with and without non-alcoholic fatty liver disease. The results showed that diabetes was associated with arterial stiffness and carotid plaque in both NAFLD and non-NAFLD participants. Longer duration of diabetes in NAFLD patients was linked to an increased risk of cardiovascular disease. The effects of diabetes on cardiovascular outcomes did not significantly differ by NAFLD status.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2021)
Article
Gastroenterology & Hepatology
Sarra Smati, Arnaud Polizzi, Anne Fougerat, Sandrine Ellero-Simatos, Yuna Blum, Yannick Lippi, Marion Regnier, Alexia Laroyenne, Marine Huillet, Muhammad Arif, Cheng Zhang, Frederic Lasserre, Alain Marrot, Talal Al Saati, JingHong Wan, Caroline Sommer, Claire Naylies, Aurelie Batut, Celine Lukowicz, Tiffany Fougeray, Blandine Tramunt, Patricia Dubot, Lorraine Smith, Justine Bertrand-Michel, Nathalie Hennuyer, Jean-Philippe Pradere, Bart Staels, Remy Burcelin, Francoise Lenfant, Jean-Francois Arnal, Thierry Levade, Laurence Gamet-Payrastre, Sandrine Lagarrigue, Nicolas Loiseau, Sophie Lotersztajn, Catherine Postic, Walter Wahli, Christophe Bureau, Maeva Guillaume, Adil Mardinoglu, Alexandra Montagner, Pierre Gourdy, Herve Guillou
Summary: The study found that different diets induced more severe NAFLD in male mice, characterized by lipid accumulation and inflammation/fibrosis. Sex-biased hepatic gene signatures showed different responses to various dietary challenges, with Peroxisome proliferator-activated receptor alpha (PPAR alpha) playing a key role in gender-specific and NAFLD pathophysiology.
Article
Biochemistry & Molecular Biology
Laura Vila, Nuria Cabedo, Carlos Villarroel-Vicente, Ainhoa Garcia, Alvaro Bernabeu, Nathalie Hennuyer, Bart Staels, Xavier Franck, Bruno Figadere, Maria-Jesus Sanz, Diego Cortes
Summary: The study synthesized three new series of prenylated benzopyrans containing different numbers of isoprenoid units and explored their hPPAR transactivation activity and structure activity relationships. The results demonstrated that 2-prenylated benzopyrans with seven-carbon and nine-carbon side chains are good lead compounds for preventing cardiovascular diseases.
BIOORGANIC & MEDICINAL CHEMISTRY
(2022)
Article
Cardiac & Cardiovascular Systems
Paolo Zanoni, Grigorios Panteloglou, Alaa Othman, Joel T. Haas, Roger Meier, Antoine Rimbert, Marta Futema, Yara Abou Khalil, Simon F. Norrelykke, Andrzej J. Rzepiela, Szymon Stoma, Michael Stebler, Freerk van Dijk, Melinde Wijers, Justina C. Wolters, Nawar Dalila, Nicolette C. A. Huijkman, Marieke Smit, Antonio Gallo, Valerie Carreau, Anne Philippi, Jean-Pierre Rabes, Catherine Boileau, Michele Visentin, Luisa Vonghia, Jonas Weyler, Sven Francque, An Verrijken, Ann Verhaegen, Luc Van Gaal, Adriaan van der Graaf, Belle V. van Rosmalen, Jerome Robert, Srividya Velagapudi, Mustafa Yalcinkaya, Michaela Keel, Silvija Radosavljevic, Andreas Geier, Anne Tybjaerg-Hansen, Mathilde Varret, Lucia Rohrer, Steve E. Humphries, Bart Staels, Bart van de Sluis, Jan Albert Kuivenhoven, Arnold von Eckardstein
Summary: This study identified a novel mechanism of posttranscriptional regulation of LDLR activity in humans and found associations of genetic variants of RBM25 with LDL-cholesterol levels.
CIRCULATION RESEARCH
(2022)
Article
Chemistry, Medicinal
Nicolas Kraupner, Chau Phi Dinh, Xiaoan Wen, Valerie Landry, Adrien Herledan, Florence Leroux, Damien Bosc, Julie Charton, Clara Maillard, Sandrine Warenghem, Isabelle Duplan, Catherine Piveteau, Nathalie Hennuyer, Bart Staels, Benoit Deprez, Rebecca Deprez-Poulain
Summary: Insulin degrading enzyme (IDE) is linked to the risk of type-2 diabetes (T2D) or Alzheimer's disease (AD). Activating IDE could be a potential therapeutic strategy for AD and also beneficial in diabetes.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Cardiac & Cardiovascular Systems
Sean M. Davidson, Chantal M. Boulanger, Elena Aikawa, Lina Badimon, Lucio Barile, Christoph J. Binder, Alain Brisson, Edit Buzas, Costanza Emanueli, Felix Jansen, Miroslava Katsur, Romaric Lacroix, Sai Kiang Lim, Nigel Mackman, Manuel Mayr, Philippe Menasche, Rienk Nieuwland, Susmita Sahoo, Kaloyan Takov, Thomas Thum, Pieter Vader, Marca H. M. Wauben, Kenneth Witwer, Joost P. G. Sluijter
Summary: This article provides an overview of the techniques and technologies available for the separation and characterization of EVs from different sources. It discusses methods for determining the protein, RNA, and lipid content of EVs. The guidance provided in this document is important for investigating the role of EVs in cardiovascular diseases and highlights key methodological issues to consider.
CARDIOVASCULAR RESEARCH
(2023)
Article
Nutrition & Dietetics
Justine Gillard, Corinne Picalausa, Christoph Ullmer, Luciano Adorini, Bart Staels, Anne Tailleux, Isabelle A. Leclercq
Summary: Activation of TGR5 has beneficial effects on glucose tolerance and MAFLD, particularly when activated in the enterohepatic system.
Article
Medicine, Research & Experimental
Alexis Boulinguiez, Christian Duhem, Alicia Mayeuf-Louchart, Benoit Pourcet, Yasmine Sebti, Kateryna Kondratska, Valerie Montel, Stephane Delhaye, Quentin Thorel, Justine Beauchamp, Aurore Hebras, Marion Gimenez, Marie Couvelaere, Mathilde Zecchin, Lise Ferri, Natalia Prevarskaya, Anne Forand, Christel Gentil, Jessica Ohana, France Pietri-Rouxel, Bruno Bastide, Bart Staels, Helene Duez, Steve Lancel
Summary: The study shows that NR1D1 plays a crucial role in regulating skeletal muscle SR calcium homeostasis by repressing the expression of the SERCA inhibitor myoregulin. Lower NR1D1 expression is observed in patients with Duchenne muscular dystrophy, while pharmacological activation of NR1D1 improves calcium homeostasis and muscle structure and function.
Article
Multidisciplinary Sciences
Marie Bobowski-Gerard, Clemence Boulet, Francesco P. Zummo, Julie Dubois-Chevalier, Celine Gheeraert, Mohamed Bou Saleh, Jean-Marc Strub, Amaury Farce, Maheul Ploton, Loic Guille, Jimmy Vandel, Antonino Bongiovanni, Ninon Very, Eloise Woitrain, Audrey Deprince, Fanny Lalloyer, Eric Bauge, Lise Ferri, Line-Carolle Ntandja-Wandji, Alexia K. Cotte, Corinne Grangette, Emmanuelle Vallez, Sarah Cianferani, Violeta Raverdy, Robert Caiazzo, Viviane Gnemmi, Emmanuelle Leteurtre, Benoit Pourcet, Rejane Paumelle, Kim Ravnskjaer, Guillaume Lassailly, Joel T. Haas, Philippe Mathurin, Francois Pattou, Laurent Dubuquoy, Bart Staels, Philippe Lefebvre, Jerome Eeckhoute
Summary: The transcription factor Basonuclin 2 (BNC2) is found to play a key role in driving myofibroblast activation in liver fibrosis. Its expression is induced in fibrotic livers and it integrates pro-fibrotic stimuli to induce matrisome gene expression. BNC2 deficiency leads to reduced collagen deposition in the liver. Furthermore, the study identifies a potential drug target, CC-885, as a BNC2 inhibitor.
NATURE COMMUNICATIONS
(2022)
Article
Endocrinology & Metabolism
Raphael Decoin, Laura Butruille, Thomas Defrancq, Jordan Robert, Nicolas Destrait, Augustin Coisne, Samy Aghezzaf, Eloise Woitrain, Zouriatou Gouda, Sofia Schino, Cedric Klein, Patrice Maboudou, Francois Brigadeau, Didier Klug, Andre Vincentelli, David Dombrowicz, Bart Staels, David Montaigne, Sandro Ninni
Summary: This study suggests that metabolic dysfunction-associated fatty liver disease (MAFLD) and liver fibrosis severity have an impact on left atrial (LA) structure and function. MAFLD patients with a high risk of F3-F4 liver fibrosis showed abnormalities in LA low-voltage areas, peak left atrial longitudinal strain, and volume, as well as a higher rate of atrial fibrillation (AF) recurrence.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Neurosciences
Veronique Ferret-Sena, Carlos Capela, Ana Macedo, Antonio Vasco Salgado, Bruno Derudas, Bart Staels, Armando Sena
Summary: This study aimed to evaluate the effects of Fingolimod treatment on PPAR and CD36 gene expression. The results showed that Fingolimod treatment increased HDL-Cholesterol and Apolipoprotein E levels, as well as leukocyte PPAR gamma and CD36 gene expression. Additionally, the variations in PPAR gamma and CD36 were significantly correlated during therapy and in patients with stable disease.
FRONTIERS IN MOLECULAR NEUROSCIENCE
(2022)
Article
Biochemistry & Molecular Biology
Angela del Castillo-Izquierdo, Jose Maria Moreno-Navarrete, Jessica Latorre, Maria Arnoriaga-Rodriguez, Marta Ballanti, Giovanni Monteleone, Omero Alessandro Paoluzi, Geltrude Mingrone, Josep Puig, Rafael Ramos, Josep Garre-Olmo, Mariona Jove, Reinald Pamplona, Manuel Portero-Otin, Joaquim Sol, Philippe Lefebvre, Bart Staels, Massimo Federici, Jose Manuel Fernandez-Real, Jordi Mayneris-Perxachs
Summary: In this study, the potential role of DPP9 in the gastrointestinal tract was explored, and its association with oxidative stress, antiviral pathways, and metabolites was identified. Promising existing drugs targeting DPP9-associated genes were also identified for potential repositioning against viral infection.
Review
Oncology
Elizabeth B. Klerman, Allison Brager, Mary A. Carskadon, Christopher M. Depner, Russell Foster, Namni Goel, Mary Harrington, Paul M. Holloway, Melissa P. Knauert, Monique K. LeBourgeois, Jonathan Lipton, Martha Merrow, Sara Montagnese, Mingming Ning, David Ray, Frank A. J. L. Scheer, Steven A. Shea, Debra J. Skene, Claudia Spies, Bart Staels, Marie-Pierre St-Onge, Steffen Tiedt, Phyllis C. Zee, Helen J. Burgess
Summary: The manuscript provides guidance on measuring metrics of endogenous circadian rhythms in humans and advocates for the inclusion of circadian rhythms assessments in health and disease studies. It describes protocols and analyses commonly used for studying human daily rhythms and recommends definitions and examples of circadian terminology.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
Article
Endocrinology & Metabolism
Stefano Rizza, Alessio Luzi, Maria Mavilio, Marta Ballanti, Arianna Massimi, Ottavia Porzio, Andrea Magrini, Juliane Hannemann, Rossella Menghini, Jonathan Cridland, Bart Staels, Peter J. Grant, Rainer H. Boger, Nikolaus Marx, Massimo Federici
Summary: This study aimed to investigate the effects of timed light therapy on rotating night shift workers. The results showed that while light therapy had no impact on inflammatory parameters or glucose tolerance, significant changes in the expression of circadian clock genes were detected in the participants' blood cells.
ACTA DIABETOLOGICA
(2022)
Article
Endocrinology & Metabolism
Carmelo Quarta, Kerstin Stemmer, Aaron Novikoff, Bin Yang, Felix Klingelhuber, Alex Harger, Mostafa Bakhti, Aimee Bastidas-Ponce, Eric Bauge, Jonathan E. Campbell, Megan Capozzi, Christoffer Clemmensen, Gustav Collden, Perla Cota, Jon Douros, Daniel J. Drucker, Barent DuBois, Annette Feuchtinger, Cristina Garcia-Caceres, Gerald Grandl, Nathalie Hennuyer, Stephan Herzig, Susanna M. Hofmann, Patrick J. Knerr, Konxhe Kulaj, Fanny Lalloyer, Heiko Lickert, Arek Liskiewicz, Daniela Liskiewicz, Gandhari Maity, Diego Perez-Tilve, Sneha Prakash, Miguel A. Sanchez-Garrido, Qian Zhang, Bart Staels, Natalie Krahmer, Richard D. DiMarchi, Matthias H. Tschoep, Brian Finan, Timo D. Mueller
Summary: A conjugate drug consisting of a GLP-1 receptor agonist and a PPAR alpha/gamma dual-agonist called tesaglitazar has been found to be more effective in treating diabetes compared to monotherapy. The drug utilizes GLP-1 receptor-dependent cellular delivery of tesaglitazar, leading to improved body weight, food intake, and glucose metabolism. It may be a promising treatment option for hyperglycemia and insulin resistance.
Article
Gastroenterology & Hepatology
Justine Gillard, Laure-Alix Clerbaux, Maxime Nachit, Christine Sempoux, Bart Staels, Laure B. Bindels, Anne Tailleux, Isabelle A. Leclercq
Summary: This study demonstrates that alterations in enterohepatic bile acids significantly contribute to the development of non-alcoholic steatohepatitis in relevant preclinical models. Experimental modulation of bile acid composition restored perturbed FXR and TGR5 signaling and prevented non-alcoholic steatohepatitis and associated metabolic disorders.
